Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FS Investment Corporation III was a non-traded business development company and specialty finance company sponsored by FS Investments. It invested primarily in debt securities of private U.S. middle-market companies, with an emphasis on generating current income and secondarily long-term capital appreciation. The company was externally managed, initially by FSIC III Advisor, LLC, with GSO / Blackstone Debt Funds Management LLC serving as sub-adviser, and later advised within the FS/KKR platform. FS Investment Corporation III was not a biotech, pharma, or healthcare operating company; it was an investment vehicle with broad private credit exposure across industries. On December 18, 2019, it was acquired in a merger led by FS Investment Corporation II, and the combined entity was renamed FS KKR Capital Corp. II.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FS Investment Corporation III.